CD134 Antibody
429€ (100 tests)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
CD134 Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx140447
tested applications
FCM
Description
CD134 Antibody is a Mouse Monoclonal antibody against CD134.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | CD134 |
| Host | Mouse |
| Reactivity | Human, Monkey |
| Recommended Dilution | FCM: 10 µl/100 µl of whole blood or 106 cells. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | APC |
| Isotype | IgG1 Kappa |
| Clone ID | O283 |
| Size 1 | 100 tests |
| Tested Applications | FCM |
| Buffer | Stabilizing PBS solution containing 15 mM sodium azide. |
| Availability | Shipped within 5-12 working days. |
| Storage | Store in the dark at 2-8°C. Avoid exposure to light. Do not freeze. |
| Dry Ice | No |
| UniProt ID | P43489 |
| Gene ID | 7293 |
| Alias | OX40,ACT35,CD134,IMD16,TXGP1L,OX40L receptor,TAX transcriptionally-activated glycoprotein 1 receptor |
| Background | Antibody anti-TNFRSF4 |
| Status | RUO |
Descripción
TNFRSF4, commonly known as OX40 (CD134), is a member of the tumor necrosis factor receptor (TNFR) superfamily. It is an important costimulatory molecule expressed on T cells, specifically induced upon T cell activation. TNFRSF4 is known for its involvement in regulating immune responses, especially in T-cell proliferation, survival, and memory formation. As an immune-regulatory receptor, it primarily interacts with its ligand, OX40L (TNFSF4), which is expressed on antigen-presenting cells (APCs), such as dendritic cells, B cells, and macrophages. OX40’s role in immune modulation is significant because it amplifies T-cell responses during both acute infections and in chronic immune responses, such as autoimmune diseases and cancer. By sustaining T-cell activation and enhancing immune memory, OX40 has become a central target in immunotherapy research, especially in the contexts of cancer immunotherapy and autoimmune diseases. Its ability to promote prolonged immune responses also makes it a critical regulator in various immune-related diseases, where modulation of OX40-OX40L interactions can potentially benefit patient outcomes.
Related Products
APC Anti-Human CD134(Ber-ACT35)
Ver Producto
Human TNFRSF4/OX40 (Tumor necrosis factor receptor superfamily member 4) ELISA Kit
Ver Producto